File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Book Chapter: Hepatitis B: Treatment
| Title | Hepatitis B: Treatment |
|---|---|
| Authors | |
| Issue Date | 12-Feb-2023 |
| Abstract | Chronic hepatitis B virus (HBV) infection is a major global health challenge. Nucleos(t)ide analog (NUC) and pegylated interferon (PEG-IFN) are currently approved antiviral therapy for chronic hepatitis B (CHB). These treatments are effective in suppressing HBV replication and reducing the risk of liver cirrhosis, liver failure, liver cancer, and death. However, neither NUC nor PEG-IFN can eliminate the virus and the risk of liver-related complications remains. Novel treatments that act by inhibiting viral replication and antigen reduction or by restoring host immune control are being actively developed in an attempt to address the unmet needs of existing treatment. Given the abundant clinical experience and real-world safety data with the currently existing therapy, any novel agents for CHB should be accompanied by strong evidence of safety. Huge efforts at the implementation of universal HBV vaccination and enhancement of linkage to care are needed to fill the remaining gaps for HBV elimination on a global level. |
| Persistent Identifier | http://hdl.handle.net/10722/341783 |
| ISBN |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Mak, LY | - |
| dc.contributor.author | Yuen, MF | - |
| dc.date.accessioned | 2024-03-26T05:37:10Z | - |
| dc.date.available | 2024-03-26T05:37:10Z | - |
| dc.date.issued | 2023-02-12 | - |
| dc.identifier.isbn | 9780323983686 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/341783 | - |
| dc.description.abstract | <p>Chronic hepatitis B virus (HBV) infection is a major global health challenge. Nucleos(t)ide analog (NUC) and pegylated interferon (PEG-IFN) are currently approved antiviral therapy for chronic hepatitis B (CHB). These treatments are effective in suppressing HBV replication and reducing the risk of liver cirrhosis, liver failure, liver cancer, and death. However, neither NUC nor PEG-IFN can eliminate the virus and the risk of liver-related complications remains. Novel treatments that act by inhibiting viral replication and antigen reduction or by restoring host immune control are being actively developed in an attempt to address the unmet needs of existing treatment. Given the abundant clinical experience and real-world safety data with the currently existing therapy, any novel agents for CHB should be accompanied by strong evidence of safety. Huge efforts at the implementation of universal HBV vaccination and enhancement of linkage to care are needed to fill the remaining gaps for HBV elimination on a global level.<span> </span></p> | - |
| dc.language | eng | - |
| dc.relation.ispartof | Comprehensive Guide to Hepatitis Advances | - |
| dc.title | Hepatitis B: Treatment | - |
| dc.type | Book_Chapter | - |
| dc.identifier.doi | 10.1016/B978-0-323-98368-6.00001-X | - |
| dc.identifier.spage | 205 | - |
| dc.identifier.epage | 227 | - |